Key Highlights

• No significant difference in mortality rates was observed between Vafseo and ESA, with rates of 8.77% and 8.78% per 100 patient years, respectively.

Trial Halted Early

Akebia Therapeutics and U.S. Renal Care revealed that the VOICE trial was discontinued ahead of schedule after an interim review. The early termination was prompted because Vafseo, an oral HIF‑prolyl hydroxylase inhibitor, fulfilled the predefined stopping thresholds for both non‑inferiority and superiority when compared with conventional erythropoiesis‑stimulating agents (ESAs).

Primary Endpoint Achieved

The primary composite outcome of the study was evaluated using a win‑odds approach. Results indicated a win odds of 1.16, with a confidence interval ranging from 1.06 to 1.28 and a p‑value of 0.0016. This statistical evidence supports the superiority claim of Vafseo over ESAs for the predefined composite of mortality and hospitalization outcomes.

Hospitalization Data

Patients receiving Vafseo experienced fewer hospital admissions than those on ESA therapy. Specifically, the Vafseo group recorded 1.11 hospitalizations per patient year, while the ESA cohort reported 1.23. The calculated incidence rate ratio was 0.90, and the associated confidence interval spanned from 0.824 to 0.988, underscoring a meaningful reduction in hospitalization risk.

Mortality Rates Unchanged

Although the hospitalization metric favoured Vafseo, mortality remained comparable across treatment arms. Mortality was 8.77% per 100 patient years for the Vafseo group and 8.78% for the ESA group. The incidence rate ratio for mortality stood at 1.00, with a confidence interval of 0.718 to 1.391, indicating no statistically significant difference.

Trial Design and Enrollment

The VOICE study enrolled a total of 2,116 participants in a randomized, open‑label, active‑controlled format. Subjects were assigned to receive Vafseo three times weekly or to continue standard ESA therapy. An independent data monitoring committee reviewed the interim data on June 1, 2026, and recommended early cessation based on the prespecified stopping criteria.

Regulatory and Market Implications

Vafseo already holds approval for anemia in dialysis‑dependent adults with CKD. The positive efficacy signals from the VOICE trial may prompt broader regulatory discussions and could influence payer decisions regarding the drug’s positioning in CKD‑related anemia treatment pathways.

Patent Protection Extended

In a separate development, Akebia Therapeutics secured an extension of patent protection for Vafseo through the year 2036. This extension reinforces the product’s exclusivity, helping to safeguard market share against potential generic competition and supporting the company’s long‑term revenue outlook.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.